AU2016264323B2 - Compositions and methods for TCR reprogramming using fusion proteins - Google Patents
Compositions and methods for TCR reprogramming using fusion proteins Download PDFInfo
- Publication number
- AU2016264323B2 AU2016264323B2 AU2016264323A AU2016264323A AU2016264323B2 AU 2016264323 B2 AU2016264323 B2 AU 2016264323B2 AU 2016264323 A AU2016264323 A AU 2016264323A AU 2016264323 A AU2016264323 A AU 2016264323A AU 2016264323 B2 AU2016264323 B2 AU 2016264323B2
- Authority
- AU
- Australia
- Prior art keywords
- cell
- domain
- tcr
- tfp
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021203052A AU2021203052A1 (en) | 2015-05-18 | 2021-05-13 | Compositions and methods for TCR reprogramming using fusion proteins |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163342P | 2015-05-18 | 2015-05-18 | |
| US62/163,342 | 2015-05-18 | ||
| PCT/US2016/033146 WO2016187349A1 (en) | 2015-05-18 | 2016-05-18 | Compositions and methods for tcr reprogramming using fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203052A Division AU2021203052A1 (en) | 2015-05-18 | 2021-05-13 | Compositions and methods for TCR reprogramming using fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016264323A1 AU2016264323A1 (en) | 2017-12-14 |
| AU2016264323A8 AU2016264323A8 (en) | 2017-12-21 |
| AU2016264323B2 true AU2016264323B2 (en) | 2021-02-18 |
Family
ID=57320750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016264323A Active AU2016264323B2 (en) | 2015-05-18 | 2016-05-18 | Compositions and methods for TCR reprogramming using fusion proteins |
| AU2021203052A Abandoned AU2021203052A1 (en) | 2015-05-18 | 2021-05-13 | Compositions and methods for TCR reprogramming using fusion proteins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203052A Abandoned AU2021203052A1 (en) | 2015-05-18 | 2021-05-13 | Compositions and methods for TCR reprogramming using fusion proteins |
Country Status (19)
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2017004252A1 (en) * | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| US12577289B2 (en) | 2015-06-30 | 2026-03-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Surrogate co-receptors for t cells and methods of use |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle ChildrenยดS Hospital Dba Seattle ChildrenยดS Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| EP3359650A4 (en) * | 2015-10-08 | 2019-03-20 | Innovative Cellular Therapeutics Co., Ltd. | ACTIVATION AND EXPANSION OF CELLS |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum MuenchenโDeutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| US10086055B2 (en) * | 2016-06-01 | 2018-10-02 | Promab Biotechnologies, Inc. | Adherent cancer cell line expressing a hematological tumor antigen |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3516068B1 (en) | 2016-09-19 | 2025-04-23 | University of Southern California | Non-radioactive cytotoxicity assays |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composiรงรตes e mรฉtodos para reprogramaรงรฃo de receptores de cรฉlula t com o uso de proteรญnas de fusรฃo |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T็ป่ๅไฝๆฒป็ๅ ฌๅธ | ็จไบไฝฟ็จ่ๅ่็ฝ่ฟ่กtcr้ๆฐ็ผ็จ็็ปๅ็ฉๅๆนๆณ |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | ๅๅ ๅฉ็ฆๅฐผไบๅคงๅญฆ | ๅๆ็ๅ ็ซๅไฝๅๅ ถไฝฟ็จๆนๆณ |
| CA3047999A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| CN116120454A (zh) * | 2017-01-05 | 2023-05-16 | ไธๆตท็ ฆ้กผๆๆฏๆ้ๅ ฌๅธ | ไบบๆบๅๆcd19ๆไฝๅๅ ถไธๅตๅๆๅๅไฝ็็จ้ |
| US20190375815A1 (en) * | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018166589A1 (en) | 2017-03-15 | 2018-09-20 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| EP3615574B1 (en) | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| WO2018200582A1 (en) * | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| PL3618842T3 (pl) * | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komรณrkowej i zwiฤ zku immunomodulujฤ cego |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e mรฉtodos para cรฉlulas manipuladas e seus usos em imuno-oncologia |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CA3064000A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DK3688032T3 (da) | 2017-09-26 | 2025-12-15 | Cero Therapeutics Holdings Inc | Kimรฆre engulfment-receptormolekyler og anvendelsesfremgangsmรฅder |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | cรฉlula imune ou populaรงรฃo de cรฉlulas imunes da mesma, cรฉlula efetora imune ou cรฉlula-tronco, cรฉlula que apresenta antรญgeno, polinucleotรญdeo recombinante, vetor, composiรงรฃo que compreende uma cรฉlula imune efetora ou uma cรฉlula-tronco, mรฉtodos para produzir uma cรฉlula efetora imune que expressa receptor imune de ocorrรชncia nรฃo natural, para gerar uma populaรงรฃo de cรฉlulas manipuladas por rna, para fornecer imunidade antidoenรงa em um indivรญduo, para tratar ou prevenir uma doenรงa associada ร expressรฃo de um antรญgeno, e, uso |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| CN110662771B (zh) | 2018-02-01 | 2023-07-28 | ๅไบฌ้ฉฏ้นฟ็็ฉๆๆฏ่กไปฝๆ้ๅ ฌๅธ | ไธ็ง็ปๅbcma็ๅตๅๆๅๅไฝ(car)ๅๅ ถๅบ็จ |
| ES2968880T3 (es) * | 2018-02-01 | 2024-05-14 | Nanjing Iaso Biotechnology Co Ltd | Receptor de antรญgeno quimรฉrico (CAR) que se une a BCMA, y usos del mismo |
| WO2019157279A1 (en) * | 2018-02-10 | 2019-08-15 | Berkeley Lights, Inc. | Mutant idh1 specific t cell receptor |
| SG11202007622SA (en) | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| BR112020016570A2 (pt) | 2018-02-17 | 2020-12-15 | Flagship Pioneering Innovations V, Inc. | Composiรงรตes e mรฉtodos para liberaรงรฃo de proteรญna de membrana |
| CA3093449A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| RU2020135107A (ru) | 2018-03-28 | 2022-04-29 | ะกะตัะพ ะขะตัะฐะฟัััะธะบั, ะะฝะบ. | ะะปะตัะพัะฝัะต ะธะผะผัะฝะพัะตัะฐะฟะตะฒัะธัะตัะบะธะต ะบะพะผะฟะพะทะธัะธะธ ะธ ะธั ะฟัะธะผะตะฝะตะฝะธั |
| MX2020010235A (es) | 2018-03-28 | 2020-10-28 | Cero Therapeutics Inc | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| JP7599205B2 (ja) | 2018-06-01 | 2024-12-13 | ใขใณใใฌใน ใปใฉใใฅใผใใฃใฏใน ใคใณใณใผใใฌใคใใใ | ็ดฐ่็ๆณใฎใใใฎๅคๆงใชๆๅ็ตๅใใกใคใณใๆฐ่ฆใใฉใใใใฉใผใ ใใใณใใฎไปใฎๅผทๅ |
| WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1ยง1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| KR20210031898A (ko) * | 2018-07-13 | 2021-03-23 | ๋์ง ๋ ์ ๋ ๋ฐ์ด์คํ ํฌ ์จ์ค., ์ํฐ๋. | ์ ์ผ๋ณ์ ์น๋ฃํ๊ธฐ ์ํ ๊ณต๋์์ฉ์ฒด ์์คํ |
| SG11202100838QA (en) * | 2018-07-26 | 2021-02-25 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using target specific fusion proteins |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | ๆฑ่ฏบๆฒป็ๅญฆ่กไปฝๆ้ๅ ฌๅธ | ๆฒป็ๅt็ป่่ฐ่็ๆนๆณๅ็ปๅ |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | ํ๋๊ทธ์ฝ ํ์ด์ด๋์ด๋ง ์ด๋ ธ๋ฒ ์ด์ ์ค ๋ธ์ด, ์ธํฌ. | ๊ตฌํ-ํน์ด์ ์นด๊ณ ์ ๋ฌ์ ์ํ ์กฐ์ฑ๋ฌผ ๋ฐ ๋ฐฉ๋ฒ |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | ไธญๅๅคงๅญฆ | ไธ็ง้็ปcar19-il24ๅบๅ ใๆ ข็ ๆฏ่ฝฝไฝใcar19-il24-t็ป่ๅๅบ็จ |
| US20230192805A1 (en) * | 2019-01-14 | 2023-06-22 | Nanjing Legend Biotech Co., Ltd. | Chimeric receptor polypeptides and uses thereof |
| WO2020167957A1 (en) * | 2019-02-12 | 2020-08-20 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| EP3715368A1 (en) | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universitรคt Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| WO2020201527A1 (en) | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| EP3959322A4 (en) * | 2019-04-22 | 2023-06-07 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| WO2020243158A1 (en) * | 2019-05-28 | 2020-12-03 | The University Of Vermont And State Agricultural College | Gamma-delta t cell ligands for cancer immunotherapy |
| WO2020264269A1 (en) | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| BR112021026832A2 (pt) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Vetores ad35 recombinantes e aprimoramentos da terapia gรชnica relacionada |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN112500492B (zh) * | 2019-09-13 | 2023-08-04 | ไธญๅฝ็งๅญฆ้ขๅๅญ็ป่็งๅญฆๅ่ถๅๆฐไธญๅฟ | ไธ็งๅตๅๆๅๅไฝๅๅ ถ็จ้ |
| US20240058446A1 (en) | 2019-10-03 | 2024-02-22 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| AU2020382219A1 (en) | 2019-11-13 | 2022-05-12 | Crispr Therapeutics Ag | Manufacturing process for making T cells expressing chimeric antigen receptors |
| CN110964122B (zh) * | 2019-12-24 | 2022-04-15 | ๅไบฌๅๆ็็ฉ็งๆๆ้ๅ ฌๅธ | T็ป่ๅไฝ่ๅ่็ฝๅๅ ถ็จ้ |
| WO2021188599A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| WO2021198163A1 (en) * | 2020-04-01 | 2021-10-07 | Medigene Immunotherapies Gmbh | Cd3-fusion protein and uses thereof |
| WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| EP4185326A1 (en) * | 2020-07-24 | 2023-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| JP7868033B2 (ja) | 2020-08-14 | 2026-06-01 | ใปใญใปใปใฉใใฅใผใใฃใฏในใปใใผใซใใฃใณใฐในใปใคใณใณใผใใฌใคใใใ | ใญใกใฉ๏ฝ๏ฝ๏ฝๅๅฎนไฝใใใณใใฎไฝฟ็จ |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| CN112521513B (zh) * | 2020-12-15 | 2021-08-24 | ้ๅฒ่ฅฟๅฏ็็ฉๆๆฏๆ้ๅ ฌๅธ | ไธ็ง้ถๅcd19็ๅตๅๆๅๅไฝ(car)ๅๅ ถๅบ็จ |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | ็พๅไธ็ดๆฒป็่กไปฝๆ้ๅ ฌๅธ | ๅ ทๆๅฏ่ชฟ้ฉๅ้ซๅฐไธๆงไนๅตๅๆๅๅ้ซ็ณป็ตฑ |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| WO2022174172A1 (en) * | 2021-02-15 | 2022-08-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Customized chimeric antigen receptor polypeptides |
| WO2022177966A1 (en) * | 2021-02-16 | 2022-08-25 | TCR2 Therapeutics Inc. | Compositions and methods for the treatment of hiv |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| WO2022192286A1 (en) * | 2021-03-09 | 2022-09-15 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and rna interference |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| FI4376874T3 (fi) | 2021-07-28 | 2026-04-08 | Cero Therapeutics Holdings Inc | Kimeerisiรค tim4-reseptoreita ja niiden kรคyttรถjรค |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ใธใผใชใผ ใปใฉใใฅใผใใฃใฏใน๏ผใคใณใณใผใใฌใคใใใ | ๆใฐใชใณ๏ฝ๏ฝ๏ฝๆไฝใใใณใใฎไฝฟ็จ |
| WO2023010436A1 (zh) * | 2021-08-05 | 2023-02-09 | ๅก็ๆต(ๅไบฌ)็ๅฝ็งๆๆ้ๅ ฌๅธ | Tcr่กจ่พพๆๅปบไฝไปฅๅๅ ถๅถๅคๆนๆณๅ็จ้ |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| JP2024534910A (ja) | 2021-09-03 | 2024-09-26 | ใธใผใชใผ ใปใฉใใฅใผใใฃใฏใน๏ผใคใณใณใผใใฌใคใใใ | ๆใฐใชใณ๏ฝ๏ฝ๏ฝ๏ฝ๏ผๆไฝใใใณใใฎไฝฟ็จ |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| US20250009800A1 (en) | 2021-11-16 | 2025-01-09 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023108150A1 (en) | 2021-12-10 | 2023-06-15 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| IL321936A (en) | 2023-01-05 | 2025-09-01 | Prec Biosciences Inc | Optimized engineered meganucleases with specificity for the human T-cell receptor alpha constant region gene |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024259371A2 (en) * | 2023-06-14 | 2024-12-19 | Duke University | COMPOSITIONS FOR AND METHODS OF EXPANDING ฮณฮด T CELLS |
| WO2025029930A1 (en) | 2023-07-31 | 2025-02-06 | Legend Biotech Ireland Limited | Cells overexpressing cd31 and methods of use thereof |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AU2025212850A1 (en) | 2024-01-26 | 2026-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025162379A1 (zh) * | 2024-02-01 | 2025-08-07 | ๆทฑๅณๅธๆตๅ ็็ฉ็งๆๆ้ๅ ฌๅธ | ไธ็งๅค่ฝๅๅ ๅซๆ่ฟฐๅค่ฝๅบๅ ็็ ๆฏ่ฝฝไฝ |
| WO2026035951A2 (en) | 2024-08-07 | 2026-02-12 | Legend Biotech Ireland Limited | Cells overexpressing cd43 and methods of use thereof |
| WO2026055226A1 (en) | 2024-09-03 | 2026-03-12 | Legend Biotech Ireland Limited | Cells overexpressing b3gnt2 and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258720A1 (en) * | 2009-05-19 | 2010-12-08 | Max Delbrรผck Centrum fรผr Molekulare Medizin (MDC) Berlin-Buch; | Multiple target T cell receptor |
Family Cites Families (269)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1009390A (en) | 1910-04-18 | 1911-11-21 | Miehle Printing Press & Mfg | Manufacture of printing-plates. |
| US1035847A (en) | 1910-05-23 | 1912-08-20 | William P Bettendorf | Means for cushioning the bodies of railway-cars. |
| US1020828A (en) | 1911-12-11 | 1912-03-19 | William A Rees | Electric washing-machine. |
| US1044284A (en) | 1912-04-29 | 1912-11-12 | Gen Electric | Heating device. |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Systรจme d'aimant ร entrefer annulaire |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5906936A (en) * | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenitรคt der variablen Antikรถrperdomรคnen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| WO1993019163A1 (en) | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) * | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| MXPA01011950A (es) | 1999-05-27 | 2002-05-06 | Gov Health & Human Serv | Inmunoconjugados que tienen alta afinidad de enlace. |
| WO2000077029A1 (en) | 1999-06-16 | 2000-12-21 | Myelos Corporation | Retro-inverso peptides derived from leukemia inhibitory factor |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | ็ป่็ๅๆญฅๅบๆฟๅๅฏ้ |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6822082B2 (en) | 2000-06-30 | 2004-11-23 | Zymogenetics, Inc. | Polynucleotides for mammalian secreted protein, Z1055G2P |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | ไธญๅฝ็งๅญฆ้ข้ไผ ไธๅ่ฒ็็ฉๅญฆ็ ็ฉถๆ | ็ฏ็ถๅ้พไธ็นๅผๆไฝ |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | ๆ ชๅผไผ็คพๆไฝ็ ็ฉถๆ | ใฉใฏใๆไฝใฉใคใใฉใชใผใฎไฝ่ฃฝๆนๆณ |
| AU2003208839A1 (en) | 2002-02-13 | 2003-09-04 | Micromet Ag | De-immunized (poly)peptide constructs |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universitรคt Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7251470B2 (en) | 2003-06-25 | 2007-07-31 | Nokia Corporation | Emergency response system with personal emergency device |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| US20050042664A1 (en) | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| DE602004027291D1 (de) | 2003-11-25 | 2010-07-01 | Us Gov Health & Human Serv | Mutierte anti-cd22-antikรถrper und immunkonjugate |
| US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| WO2006018833A2 (en) | 2004-08-16 | 2006-02-23 | Tadiran Spectralink Ltd. | A wearable device, system and method for measuring a pulse while a user is in motion |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| WO2006124641A2 (en) | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | ์๋ณดํธ ๋ฌ๋ณด๋ฌํฐ๋ฆฌ์ฆ | ์ด์ ๊ฐ๋ณ ๋๋ฉ์ธ ๋ฉด์ญ๊ธ๋ก๋ถ๋ฆฐ ๋ฐ ์ด์ ์ฉ๋ |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| GB0721686D0 (en) | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| KR101559599B1 (ko) | 2007-11-26 | 2015-10-12 | ๋ฐ์ด์ ์ธํ ๋ ์ณ ํ๋กํผํฐ ๊ฒ์ ๋ฒ ํ | ํญ-๋ฉ์ํ ๋ฆฐ ํญ์ฒด ๋ฐ ์ด์ ์ฉ๋ |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| KR20090092900A (ko) | 2008-02-28 | 2009-09-02 | ์ ์คํธ | ์ด๋ฆฐ์ด ๋ฐ ๋ ธ์ฝ์ ์์ ๋ณดํธ์์คํ |
| US20090322513A1 (en) | 2008-06-27 | 2009-12-31 | Franklin Dun-Jen Hwang | Medical emergency alert system and method |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101837053B1 (ko) | 2008-10-01 | 2018-03-12 | ์์ ๋ฆฌ์์น (๋ฎํจ) ๊ฒ์ ๋ฒ ํ | ์ข ๊ฐ ํน์ด์ ๏ผฐ๏ผณ๏ผฃ๏ผก๏ฝ๏ผฃ๏ผค๏ผ, ๏ผฃ๏ผค19๏ฝ๏ผฃ๏ผค3, ๏ฝ-๏ผญ๏ผฅ๏ผด๏ฝ๏ผฃ๏ผค3, ์๋์์๋ฆฐ๏ฝ๏ผฃ๏ผค3, ๏ผฅ๏ฝ๏ผฃ๏ผก๏ผญ๏ฝ๏ผฃ๏ผค3, ๏ผฉ๏ผง๏ผฆ-1๏ผฒ๏ฝ๏ผฃ๏ผค3 ๋๋ ๏ผฆ๏ผก๏ผฐฮฑ๏ฝ๏ผฃ๏ผค3 ์ด์คํน์ด์ ๋จ์ผ์ ํญ์ฒด |
| HUE043326T2 (hu) * | 2008-11-07 | 2019-08-28 | Amgen Res Munich Gmbh | Akut limfoblasztos leukรฉmia kezelรฉse |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| CN102421801B (zh) * | 2009-03-10 | 2016-03-16 | ๆฏๅฅฅๆ นMaๅ ฌๅธ | ๆ-bcmaๆไฝ |
| US9316646B2 (en) | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
| US20130066283A1 (en) | 2009-10-23 | 2013-03-14 | Nexisvision, Inc. | Corneal Denervation for Treatment of Ocular Pain |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| LT2361936T (lt) | 2010-02-25 | 2016-09-12 | Affimed Gmbh | Antigenฤ riลกanti molekulฤ ir jos panaudojimas |
| CA2793753C (en) | 2010-03-26 | 2018-06-05 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| WO2012008860A2 (en) | 2010-07-16 | 2012-01-19 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
| EP2614143B1 (en) | 2010-09-08 | 2018-11-07 | Baylor College Of Medicine | Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells |
| CA2816379A1 (en) | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| EP3018145B1 (en) | 2010-10-27 | 2018-04-04 | Amgen Research (Munich) GmbH | Means and methods for treating dlbcl |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| AU2011349443B2 (en) | 2010-12-20 | 2015-12-24 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ใถ ใใฉในใใฃใผใบ ใชใ ใถ ใฆใใใผใทใใฃ ใชใ ใใณใทใซใใใข | ็ใๆฒป็ใใใใใฎ็ตๆ็ฉใใใณๆนๆณ |
| ES2588730T3 (es) | 2011-03-17 | 2016-11-04 | Miltenyi Biotec Gmbh | Preparados celulares agotados en lo que respecta a TCRalfa/beta |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | ๋ ํธ๋ฌ์คํฐ์ค ์ค๋ธ ๋ ์ ๋๋ฒ์ํฐ ์ค๋ธ ํ์ค๋ฐ๋์ | ์์ ์น๋ฃํ๊ธฐ ์ํ rna ์กฐ์๋ t ์ธํฌ |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ใใทใงใใซ ใญใฃใณใตใผ ใปใณใฟใผ | ๅค็ฐ๏ฝ๏ฝ๏ฝ๏ฝ๏ผ้บไผๅญ็งปๅ ฅ๏ฝ็ดฐ่ๅใณใใใๅซใๆใใๅ ็ซๆฒป็็จ็ตๆ็ฉ |
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | ็พๅๅฎ้ฒ่กไปฝๆ้ๅ ฌๅธ | ้ๅฐ๏ฝ๏ฝ๏ฝ๏ฝไนe3ไปฅๅ๏ฝ๏ฝ๏ผ็็ตๅๅๅญ |
| AR089114A1 (es) | 2011-12-09 | 2014-07-30 | Amgen Res Munich Gmbh | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR112014020502A2 (pt) | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequรชncia de รกcido nucleico isolada, receptor quimรฉrico de antรญgeno isolado, cรฉlula, vetor, e, mรฉtodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamรญfero, para gerar e para expandir uma populaรงรฃo de cรฉlulas - t, e para modular a quantidade de citocina secretada por uma cรฉlula -t |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9127081B2 (en) | 2012-05-10 | 2015-09-08 | Washington University | Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | ๋ ํธ๋ฌ์คํฐ์ค ์ค๋ธ ๋ ์ ๋๋ฒ์ํฐ ์ค๋ธ ํ์ค๋ฐ๋์ | ์ด์คํน์ด์ ํญ์ฒด์ ๊ณต-๋์ ์ ์ํ ๏ฝ๏ฝ๏ฝ ์ธํฌ์ ํ์ฑ ์ฆ๊ฐ |
| KR20210149195A (ko) | 2012-07-13 | 2021-12-08 | ๋ ํธ๋ฌ์คํฐ์ค ์ค๋ธ ๋ ์ ๋๋ฒ์ํฐ ์ค๋ธ ํ์ค๋ฒ ๋์ | ํ์ง๋์ ๋ ๏ฝ ์ธํฌ์ ํฌ์ฌ ์ ํฉ์ฑ์ ํ๊ฐํ๋ ๋ฐฉ๋ฒ |
| EP2872617A4 (en) | 2012-07-13 | 2015-12-09 | Univ Pennsylvania | EPITOP SPREADING IN CONNECTION WITH CAR T CELLS |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Lฤ stelinฤs imunoterapijos bลซdas ir kompozicijos |
| US9416190B2 (en) | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | ะะตะผะพัะธะฐะป ะกะปะพะฐะฝ-ะะตััะตัะธะฝะณ ะัะฝัะตั ะกะตะฝัะตั | ะะพะผะฟะพะทะธัะธะธ ะธ ัะฟะพัะพะฑั ะดะปั ะธะผะผัะฝะพัะตัะฐะฟะธะธ |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | ใจใณใฏใใ ใจในใขใผใจใผใซใจใซ | ๏ผข๏ฝ๏ฝ๏ฝใซๅฏพใใๆไฝใฎ้ธๆใฎใใใฎๆนๆณ |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| WO2014130635A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2014134412A1 (en) | 2013-03-01 | 2014-09-04 | Regents Of The University Of Minnesota | Talen-based gene correction |
| US20160015749A1 (en) | 2013-03-05 | 2016-01-21 | Baylor College Of Medicine | Engager cells for immunotherapy |
| AU2014386824B2 (en) | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Molรฉculas de uniรณn para bcma y cd3 |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor ฮฒ |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cรกncer utilizando un receptor quimรฉrico de antรญgeno anti-cd19 |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifiฤni himerni antigenski receptor in njegova uporaba |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | ใปใฌใฏใใฃใน | ๏ผฒ๏ฝ๏ฝใฌใคใ๏ฝ๏ฝ๏ฝใใฏใฌใขใผใผ็ณปใ็จใใใใจใซใใฃใฆๅ ็ซ็ๆณใฎใใใซ๏ฝ็ดฐ่ใๆไฝใใใใใฎๆนๆณ |
| BR112016000666A2 (pt) | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligaรงรฃo de antรญgeno cd3 e cd19 biespecรญficos |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | ์ธ์ดํฐ์ค ํ ๋ผํจํฑ์ค, ์ธํฌ. | ๋งคํธ๋ฆญ์ค ๋ฉํ๋กํ๋กํ ์ด๋์ ๊ธฐ์ง ๋ฐ ๋ค๋ฅธ ์ ๋จ์ฑ ๋ชจ์ด์ดํฐ ๋ฐ ์ด์ ์ฌ์ฉ ๋ฐฉ๋ฒ |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2014337385B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| AU2014337367B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| AU2015206040B2 (en) | 2014-01-14 | 2018-11-01 | Cellectis | Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | ็พๅๅ็ๅ ้ซ่ฅๅ ฌๅธ | ้ๅฐ๏ฝ๏ฝ-๏ผ็ไบบ้กๆ้ซ |
| CA2936984A1 (en) | 2014-01-24 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | ์นด์ดํธ ํ๋ง ์ธ์ฝํฌ๋ ์ดํฐ๋ | B ์ธํฌ ์ ์ฑ์ข ์ ๋ฐ ๋ค๋ฅธ ์์ ์น๋ฃํ๋๋ฐ ์ ์ฉํ ์๊ฐ t ์ธํฌ ๋ฐ ๊ทธ์ ์กฐ์ฑ๋ฌผ์ ์์ฐ ๋ฐฉ๋ฒ |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimรฆre antigenreceptorer og fremgangsmรฅder til fremstilling heraf |
| JP6665102B2 (ja) | 2014-02-21 | 2020-03-13 | ใปใฌใฏใใฃใน๏ผฃ๏ฝ ๏ฝ๏ฝ๏ฝ ๏ฝ๏ฝ๏ฝ๏ฝ | ๅถๅพกๆง๏ฝ็ดฐ่ใใคใณใตใคใใฅใผใง้ปๅฎณใใใใใฎๆนๆณ |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | ๊ตญ๋ฆฝ์์ผํฐ | B ์ธํฌ ๋ฆผํ์ข ์ธํฌ๋ฅผ ํน์ด์ ์ผ๋ก ์ธ์งํ๋ ๋จ์ผํด๋ก ํญ์ฒด ๋ฐ ์ด์ ์ฉ๋ |
| WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | ่ฏบๅ่กไปฝๆ้ๅ ฌๅธ | ไฝฟ็จๅตๅๆๅๅไฝๆฒป็็็ |
| CN106459165B (zh) | 2014-04-01 | 2021-04-20 | ๆๆฉ็งๆ็ป่&ๅบๅ ๆฒป็ๆ้ๅ ฌๅธ | ๅฏๅฐ่็ฝ-6็นๅผๆงๅ ็ซๅไฝๅt็ป่่กจไฝ |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| WO2015164759A2 (en) | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Mnd promoter chimeric antigen receptors |
| CN106456670B (zh) | 2014-04-25 | 2020-01-07 | ่้ธ็็ฉๅ ฌๅธ | ๅถๅค่ฟ็ปงๆง็ป่็ๆณ็ๆนๅๆนๆณ |
| EP3166968B1 (en) | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| US11041021B2 (en) | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| US10287360B2 (en) | 2014-05-23 | 2019-05-14 | INSERM (Institut National de la Santรฉ et de la Recherche Mรฉdicale | Anti-EGFR conformational single domain antibodies and uses thereof |
| WO2015188141A2 (en) | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| US10752684B2 (en) | 2014-07-29 | 2020-08-25 | Cellectis | ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3177711B1 (en) | 2014-08-07 | 2024-04-24 | Northwestern University | Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells |
| WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universitรคt Mรผnchen | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| CA2957929A1 (en) | 2014-08-12 | 2016-02-18 | Anthrogenesis Corporation | Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimรฆriske antigenreceptorer til modificerede t-celler |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antรญgeno quimรฉrico coestimulante que se dirigen a IL13R 2 |
| WO2016054520A2 (en) * | 2014-10-03 | 2016-04-07 | The California Institute For Biomedical Research | Engineered cell surface proteins and uses thereof |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| BR112017008042A2 (pt) | 2014-10-20 | 2017-12-26 | Juno Therapeutics Inc | mรฉtodos e composiรงรตes para dosagem em terapia de cรฉlula adotiva |
| PL3212225T3 (pl) โ | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytรณw t |
| WO2016073381A1 (en) | 2014-11-03 | 2016-05-12 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| JP6740234B2 (ja) | 2014-11-05 | 2020-08-12 | ใธใฅใใผ ใปใฉใใฅใผใใฃใฏใน ใคใณใณใผใใฌใคใใใ | ๅฝข่ณชๅฐๅ ฅใใใณ็ดฐ่ใใญใปใทใณใฐใฎใใใฎๆนๆณ |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| DK3227339T3 (da) | 2014-12-05 | 2022-01-10 | Memorial Sloan Kettering Cancer Center | Kimรฆriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | ็บชๅฟตๆฏ้-ๅฏ็น็ณ็็ไธญๅฟ | ้ถๅb-็ป่ๆ็ๆๅ็ๅตๅๆๅๅไฝๅๅ ถ็จ้ |
| US20170296623A1 (en) | 2014-12-17 | 2017-10-19 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| EP3037170A1 (en) | 2014-12-27 | 2016-06-29 | Miltenyi Biotec GmbH | Multisort cell separation method |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | ะะพะฒะฐััะธั ะะณ | ะกะฟะพัะพะฑั ะฟะพะปััะตะฝะธั ัะบัะฟัะตััะธััััะธั ั ะธะผะตัะฝัะน ะฐะฝัะธะณะตะฝะฝัะน ัะตัะตะฟัะพั ะบะปะตัะพะบ |
| WO2016115274A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| GB201501175D0 (en) | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
| EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016123675A1 (en) | 2015-02-05 | 2016-08-11 | The University Of Queensland | Targeting constructs for delivery of payloads |
| AU2016215110A1 (en) | 2015-02-05 | 2017-09-21 | Stc.Unm | Anti-pre-BCR antagonists and methods |
| US20160228547A1 (en) | 2015-02-06 | 2016-08-11 | Batu Biologics, Inc. | Chimeric antigen receptor targeting of tumor endothelium |
| US10647778B2 (en) | 2015-02-09 | 2020-05-12 | University Of Florida Research Foundation, Incorporated | Bi-specific chimeric antigen receptor and uses thereof |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| US20160237407A1 (en) | 2015-02-17 | 2016-08-18 | Batu Biologics, Inc. | Universal donor chimeric antigen receptor cells |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3262166A4 (en) | 2015-02-24 | 2018-08-15 | The Regents of The University of California | Binding-triggered transcriptional switches and methods of use thereof |
| BR112017018770A2 (pt) | 2015-03-02 | 2018-04-17 | Innovative Cellular Therapeutics CO., LTD. | reduรงรฃo da tolerรขncia imunolรณgica induzida por pd-l1 |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| KR20170134525A (ko) | 2015-04-02 | 2017-12-06 | ๋ฉ๋ชจ๋ฆฌ์ผ ์ฌ๋ก์-์ผํฐ๋ง ์บ์ ์ผํฐ | Tnfrsf14 / hvem ๋จ๋ฐฑ์ง ๋ฐ ์ด์ ์ด์ฉ ๋ฐฉ๋ฒ |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteรญnas de fusรฃo pd-1-cd28 e a sua utilizaรงรฃo em medicina |
| JP6974311B2 (ja) | 2015-06-23 | 2021-12-01 | ใกใขใชใขใซ ในใญใผใณ ใฑใฟใชใณใฐ ใญใฃใณใตใผ ใปใณใฟใผ | ๆฐ่ฆ๏ฝ๏ฝโ๏ผๅ ็ซ่ชฟ็ฏๅค |
| MX2018000278A (es) | 2015-06-29 | 2018-03-08 | Univ Johns Hopkins | Terapia de receptores quimericos de puntos de control inmunitarios. |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| CN106519037B (zh) | 2015-09-11 | 2019-07-23 | ็งๆต็็ฉๅป่ฏ๏ผไธๆตท๏ผๆ้ๅ ฌๅธ | ๅฏๆดปๅ็ๅตๅๅไฝ |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Cรฉlulas genรฉticamente modificadas que comprenden un gen de regiรณn constante alfa del receptor de linfocitos T humano modificado |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | ็งๆต็็ฉๅป่ฏ๏ผไธๆตท๏ผๆ้ๅ ฌๅธ | ๆบๅธฆpd-l1้ปๆญๅ็ๅตๅๆๅๅไฝไฟฎ้ฅฐ็ๅ ็ซๆๅบ็ป่ |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | ็บชๅฟตๆฏ้-ๅฏ็นๆ็็ไธญๅฟ | ๅ ็ซ็ป่็ปๅ็ฉๅๅ ถไฝฟ็จๆนๆณ |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigรฉnio quimรฉrico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilizaรงรฃo combinada em terapia anticancerรญgena |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | ๅ ็ซๅป็ๅ ฌๅธ | Abcg2ๆๅถๅไธsacituzumab govitecan(immu-132)็็ปๅๅ ๆ่กจ่พพtrop-2็็ไธญๅฏนsn-38็ๆๆง |
| WO2017162587A1 (en) | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| US11365237B2 (en) | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum MuenchenโDeutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | ์นด์ดํธ ํ๋ง ์ธ์ฝํฌ๋ ์ดํฐ๋ | ํค๋ฉ๋ผ ํญ์ ๋ฐ t ์ธํฌ ์์ฉ์ฒด ๋ฐ ์ฌ์ฉ ๋ฐฉ๋ฒ |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3034691A1 (en) | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| BR112019007100A2 (pt) * | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composiรงรตes e mรฉtodos para reprogramaรงรฃo de receptores de cรฉlula t com o uso de proteรญnas de fusรฃo |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T็ป่ๅไฝๆฒป็ๅ ฌๅธ | ็จไบไฝฟ็จ่ๅ่็ฝ่ฟ่กtcr้ๆฐ็ผ็จ็็ปๅ็ฉๅๆนๆณ |
| CA3047999A1 (en) | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| WO2018119198A1 (en) | 2016-12-22 | 2018-06-28 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| EP3572427B1 (en) | 2017-01-23 | 2025-06-25 | CRAGE medical Co., Limited | Bcma-targeting antibody and use thereof |
| WO2018189360A1 (en) | 2017-04-13 | 2018-10-18 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | cรฉlula imune ou populaรงรฃo de cรฉlulas imunes da mesma, cรฉlula efetora imune ou cรฉlula-tronco, cรฉlula que apresenta antรญgeno, polinucleotรญdeo recombinante, vetor, composiรงรฃo que compreende uma cรฉlula imune efetora ou uma cรฉlula-tronco, mรฉtodos para produzir uma cรฉlula efetora imune que expressa receptor imune de ocorrรชncia nรฃo natural, para gerar uma populaรงรฃo de cรฉlulas manipuladas por rna, para fornecer imunidade antidoenรงa em um indivรญduo, para tratar ou prevenir uma doenรงa associada ร expressรฃo de um antรญgeno, e, uso |
| GB201800298D0 (en) | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| MX2020008184A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| CA3093449A1 (en) | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2019222275A2 (en) | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| SG11202100838QA (en) | 2018-07-26 | 2021-02-25 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using target specific fusion proteins |
| KR102879284B1 (ko) | 2018-08-29 | 2025-10-31 | ๋์ง ๋ ์ ๋ ๋ฐ์ด์คํ ํฌ ์จ์ค., ์ํฐ๋. | ํญ-๋ฉ์ํ ๋ฆฐ ํค๋ฉ๋ผ ํญ์ ์์ฉ์ฒด(car) ์์ ๋ฌผ ๋ฐ ์ด์ ์ฉ๋ |
| SG11202101811VA (en) | 2018-08-30 | 2021-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
| CN114206357A (zh) | 2019-03-22 | 2022-03-18 | T็ป่ๅไฝๆฒป็ๅ ฌๅธ | ไฝฟ็จ่ๅ่็ฝ่ฟ่กtcr้็ผ็จ็็ปๅ็ฉๅๆนๆณ |
| EP3959322A4 (en) | 2019-04-22 | 2023-06-07 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20210130438A1 (en) | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| US20230338421A1 (en) | 2020-01-10 | 2023-10-26 | TCR2 Therapeutics Inc. | Compositions and methods for autoimmunity regulation |
| WO2021155034A1 (en) | 2020-01-29 | 2021-08-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using muc16 specific fusion proteins |
| WO2021226289A2 (en) | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| EP4185326A1 (en) | 2020-07-24 | 2023-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| WO2022056321A1 (en) | 2020-09-10 | 2022-03-17 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins |
| WO2022177966A1 (en) | 2021-02-16 | 2022-08-25 | TCR2 Therapeutics Inc. | Compositions and methods for the treatment of hiv |
| US20230065936A1 (en) | 2021-04-09 | 2023-03-02 | Tcr2 Therapeutics Inc | Compositions and methods for treating cancer |
| WO2023044039A1 (en) | 2021-09-16 | 2023-03-23 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
-
2016
- 2016-05-18 EP EP20180627.0A patent/EP3770168A1/en not_active Withdrawn
- 2016-05-18 HU HUE16797244A patent/HUE051661T2/hu unknown
- 2016-05-18 CN CN202210028922.8A patent/CN114634943A/zh active Pending
- 2016-05-18 ES ES16797244T patent/ES2819976T5/es active Active
- 2016-05-18 EP EP18207665.3A patent/EP3466967A1/en not_active Withdrawn
- 2016-05-18 DK DK16797244.7T patent/DK3298033T4/da active
- 2016-05-18 SG SG10201914069SA patent/SG10201914069SA/en unknown
- 2016-05-18 WO PCT/US2016/033146 patent/WO2016187349A1/en not_active Ceased
- 2016-05-18 KR KR1020177036173A patent/KR20180029201A/ko not_active Ceased
- 2016-05-18 JP JP2017560616A patent/JP2018515123A/ja not_active Withdrawn
- 2016-05-18 IL IL255697A patent/IL255697B2/en unknown
- 2016-05-18 EA EA202090931A patent/EA202090931A3/ru unknown
- 2016-05-18 CN CN201680032042.0A patent/CN107995913B/zh active Active
- 2016-05-18 EA EA201792420A patent/EA035618B1/ru unknown
- 2016-05-18 AU AU2016264323A patent/AU2016264323B2/en active Active
- 2016-05-18 PL PL16797244.7T patent/PL3298033T5/pl unknown
- 2016-05-18 BR BR112017024757-7A patent/BR112017024757A2/pt not_active IP Right Cessation
- 2016-05-18 MX MX2017014822A patent/MX2017014822A/es unknown
- 2016-05-18 IL IL303905A patent/IL303905A/en unknown
- 2016-05-18 EP EP16797244.7A patent/EP3298033B2/en active Active
- 2016-05-18 FI FIEP16797244.7T patent/FI3298033T4/fi active
- 2016-05-18 PT PT167972447T patent/PT3298033T/pt unknown
-
2017
- 2017-01-30 US US15/419,398 patent/US10442849B2/en active Active
- 2017-11-24 ZA ZA2017/08000A patent/ZA201708000B/en unknown
-
2018
- 2018-04-27 US US15/965,738 patent/US10358473B2/en active Active
- 2018-04-27 US US15/965,739 patent/US10358474B2/en active Active
-
2019
- 2019-06-10 US US16/436,110 patent/US20210206827A9/en not_active Abandoned
-
2020
- 2020-08-10 US US16/989,602 patent/US11028142B2/en active Active
-
2021
- 2021-05-13 AU AU2021203052A patent/AU2021203052A1/en not_active Abandoned
- 2021-07-29 JP JP2021124590A patent/JP7047172B2/ja active Active
- 2021-08-26 JP JP2021138030A patent/JP7262535B2/ja active Active
-
2022
- 2022-12-21 US US18/069,749 patent/US11965012B2/en active Active
-
2023
- 2023-04-07 JP JP2023062797A patent/JP2023085509A/ja active Pending
-
2024
- 2024-03-08 US US18/600,309 patent/US20240301026A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258720A1 (en) * | 2009-05-19 | 2010-12-08 | Max Delbrรผck Centrum fรผr Molekulare Medizin (MDC) Berlin-Buch; | Multiple target T cell receptor |
Non-Patent Citations (1)
| Title |
|---|
| Nolan, K.F. et al., "Bypassing Immunization: Optimized Design of "Designer T cells" against Carcinoembryonic Antigen (CEA)-expressing Tumours, and Lack of Suppression by Soluble CEA", Clinical Cancer Research, (1999) Vol. 5, pages 3928-3941 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11965012B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| AU2019203955B2 (en) | Multipartite signaling proteins and uses thereof | |
| KR102319845B1 (ko) | ์กฐ๋ฅ ์์ฃผ ์ธํฌ์ ๋ํ crispr-cas ์์คํ | |
| KR20210108423A (ko) | ์๋ฐ๋ ธ ๊ด๋ จ ๋ฐ์ด๋ฌ์ค (aav) ์์ฐ์ ์ธํฌ์ฃผ ๋ฐ ๊ด๋ จ ๋ฐฉ๋ฒ | |
| KR102006527B1 (ko) | ์ ๋ฆฝ์ -์ฐ๊ด ํญ์์ ๋ฐํ์ ์ํ ๋ฒกํฐ | |
| KR20100087303A (ko) | ์๋ฌผ์น๋ฃํ์ ๋ถ์๋ฅผ ๋ฐํ์ํค๊ธฐ ์ํ ์น๋ฃํ์ ์ ์ ์-์ค์์น ์์ ๋ฌผ ๋ฐ ์๋ฌผ๋ฐ์๊ธฐ, ๋ฐ ์ด์ ์ฉ๋ | |
| KR20230019063A (ko) | C9orf72 ์ฐ๊ด ์งํ์ ์น๋ฃ๋ฅผ ์ํ ์ผ์ค ๊ธฐ๋ฅ ์๋ฐ๋ ธ-์ฐ๊ด ๋ฐ์ด๋ฌ์ค (aav) ๋ฒกํฐ | |
| CN114026242A (zh) | ๅ ทๆ้ซ้่็ฝ้ถๅฏๅจๅญ็aav่ฝฝไฝๅๅ ถ็จไบๆฒป็้ชๆบ็ป่็ธๅ ณ็พ็ ๅฆcharcot-marie-tooth็พ็ ็็จ้ | |
| KR20240037185A (ko) | ํค๋ฉ๋ผ ๊ณต๋์๊ทน ์์ฉ์ฒด, ์ผ๋ชจ์นด์ธ ์์ฉ์ฒด, ๋ฐ ์ธํฌ ๋ฉด์ญ์น๋ฃ์์์ ์ด์ ์ฉ๋ | |
| KR20230117327A (ko) | ๊ฐ์ฉ์ฑ ์์นผ๋ฆฌ์ฑ ํฌ์คํํ์ ์์ ๋ฌผ ๋ฐ ๊ฐ์ฉ์ฑ ์์นผ๋ฆฌ์ฑ ํฌ์คํํ์ ์์ ๋ฌผ์ ์ธ์ฝ๋ฉํ๋ ํด๋ฆฌ๋ดํด๋ ์คํฐ๋๋ฅผ ํฌํจํ๋ ๋ฐํ ๋ฒกํฐ | |
| AU2020344628A1 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| AU2017233862B2 (en) | Methods and compositions for increased double stranded RNA production | |
| KR20240022571A (ko) | Rna-๊ฐ์ด๋๋ ์ดํํฐ ๋์์ ์ํ ์์คํ , ๋ฐฉ๋ฒ ๋ฐ ์ฑ๋ถ | |
| AU2020327783B2 (en) | Oncolytic vaccinia virus | |
| US20240165154A1 (en) | Methods and agents for modulating adoptive immunotherapy | |
| CA2522166C (en) | Lambda integrase mutein for use in recombination | |
| HK40091834A (en) | Methods and compositions for increased double stranded rna production | |
| HK40049685A (en) | Adeno-associated virus (aav) producer cell line and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 31 , NO 49 , PAGE(S) 7157 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TCR2 THERAPEUTICS, INC., APPLICATION NO. 2016264323, UNDER INID (71) CORRECT THE APPLICANT NAME TO TCR2 THERAPEUTICS INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |